HIMS Stock Recent News
HIMS LATEST HEADLINES
NEW YORK , July 8, 2025 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Hims & Hers Health, Inc. (NYSE: HIMS) Shareholders should email Fletcher@fmoorelaw.com The investigation concerns a recent announcement about the Novo Nordisk collaboration. On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.
As tariff fears ripple across markets with President Donald Trump sending tariff letters to 12 countries, small-cap resilience is stealing the spotlight. The Russell 2000 index is soaring toward creating new all-time highs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 8, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting retention and average revenue per user to $84. Despite the Novo Nordisk split, the diversified GLP-1 and weight loss portfolio targets $725 million in 2025 specialty revenue.
NEW YORK , July 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025.
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
BMBL, HBM, HIMS, BWMX and ERO have been added to the Zacks Rank #1 (Strong Buy) List on July 8, 2025.
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).
PHILADELPHIA , July 7, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Investor Deadline: Investors who purchased or acquired Hims & Hers securities between April 29, 2025 and June 22, 2025 (the "Class Period") may, no later than August 25, 2025 , seek to be appointed as a lead plaintiff representative of the class.